iSpecimen 3Q 2026: Revenue $244.03K, EPS ($1.03) — 10-Q Summary
iSpecimen reported 3Q 2026 revenue of $244.03K, up 129% YoY, with specimen count rising 169% to 752. Net loss narrowed 20% due to lower operating expenses. Sales and marketing costs increased 21%, while technology and administrative expenses fell. Quote-to-purchase conversion ratio improved to 44%.

